Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.
Johnson & Johnson on Tuesday boosted its 2019 sales forecast amid robust demand for its cancer drugs, but warned that competition from generic and copycat drugs could impact its third-quarter results, sending shares down 1.4% in noon trading.
* Indexes up: Dow 0.58%, S&P 0.21%, Nasdaq 0.40%
(Updates to early afternoon)
Karyopharm Therapeutics Inc on Wednesday set a list-price for its blood cancer treatment Xpovio at $22,000 per month, following accelerated approval from the U.S. Food and Drug Administration.
July 3 The U.S. Food and Drug Administration on
Wednesday approved Karyopharm Therapeutics Inc's
treatment for multiple myeloma, a type of blood cancer.
Family background can matter for the health of diabetic children, according to researchers in Denmark who found young patients' blood sugar control was linked with the level of education their mothers had attained.
Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc .
Walgreens Boots Alliance Inc on Thursday posted a better-than-expected quarterly profit as the drugstore chain benefited from a rise in branded drug prices and an increase in the number of prescriptions it fills in the United States.
(Reuters Health) - Older adults who come to U.S. emergency rooms often have trouble affording medications, a study shows.
Shares of Chewy Inc soared 63% in their public debut, giving the online pet products retailer a market value of $14.35 billion, more than four times the price PetSmart paid for it in 2017. | Video